203 related articles for article (PubMed ID: 26382939)
21. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats.
Sharma B; Singh N
Psychopharmacology (Berl); 2011 Jun; 215(4):677-87. PubMed ID: 21225418
[TBL] [Abstract][Full Text] [Related]
22. Pitavastatin and 4'-hydroxy-3'-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes.
Sharma B; Singh N
Curr Neurovasc Res; 2010 Aug; 7(3):180-91. PubMed ID: 20560881
[TBL] [Abstract][Full Text] [Related]
23. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
Chinda K; Palee S; Surinkaew S; Phornphutkul M; Chattipakorn S; Chattipakorn N
Int J Cardiol; 2013 Jul; 167(2):451-7. PubMed ID: 22285447
[TBL] [Abstract][Full Text] [Related]
24. Melatonin receptor and KATP channel modulation in experimental vascular dementia.
Singh P; Gupta S; Sharma B
Physiol Behav; 2015 Apr; 142():66-78. PubMed ID: 25659733
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
Ittichaicharoen J; Apaijai N; Tanajak P; Sa-Nguanmoo P; Chattipakorn N; Chattipakorn S
Arch Oral Biol; 2018 Jan; 85():148-153. PubMed ID: 29073562
[TBL] [Abstract][Full Text] [Related]
26. Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart.
Chinda K; Sanit J; Chattipakorn S; Chattipakorn N
Diab Vasc Dis Res; 2014 Mar; 11(2):75-83. PubMed ID: 24357666
[TBL] [Abstract][Full Text] [Related]
27. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
Jin HY; Liu WJ; Park JH; Baek HS; Park TS
Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866
[TBL] [Abstract][Full Text] [Related]
28. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.
Kosaraju J; Murthy V; Khatwal RB; Dubala A; Chinni S; Muthureddy Nataraj SK; Basavan D
J Pharm Pharmacol; 2013 Dec; 65(12):1773-84. PubMed ID: 24117480
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective Effects of Nicorandil in Chronic Cerebral Hypoperfusion-Induced Vascular Dementia.
Gupta S; Singh P; Sharma B
J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2717-2728. PubMed ID: 27622862
[TBL] [Abstract][Full Text] [Related]
30. Experimental hypertension induced vascular dementia: pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor.
Sharma B; Singh N
Pharmacol Biochem Behav; 2012 Jul; 102(1):101-8. PubMed ID: 22507914
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
32. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
Matsui T; Nishino Y; Takeuchi M; Yamagishi S
Pharmacol Res; 2011 May; 63(5):383-8. PubMed ID: 21320599
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
34. Neurobehavioral and neurobiochemical effect of atomoxetine and N-acetylcysteine in streptozotocin diabetes induced endothelial dysfunction and related dementia.
Aggarwal H; Gupta S; Sharma P; Sharma BM; Sharma B
Physiol Behav; 2022 May; 249():113767. PubMed ID: 35245527
[TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
Boschmann M; Engeli S; Dobberstein K; Budziarek P; Strauss A; Boehnke J; Sweep FC; Luft FC; He Y; Foley JE; Jordan J
J Clin Endocrinol Metab; 2009 Mar; 94(3):846-52. PubMed ID: 19088168
[TBL] [Abstract][Full Text] [Related]
36. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver.
Asakura M; Fujii H; Atsuda K; Itoh T; Fujiwara R
Drug Metab Dispos; 2015 Apr; 43(4):477-84. PubMed ID: 25597851
[TBL] [Abstract][Full Text] [Related]
38. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited.
Burkey BF; Hoffmann PK; Hassiepen U; Trappe J; Juedes M; Foley JE
Diabetes Obes Metab; 2008 Nov; 10(11):1057-61. PubMed ID: 18422675
[TBL] [Abstract][Full Text] [Related]
39. Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and β-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
Sato K; Nakamura A; Shirakawa J; Muraoka T; Togashi Y; Shinoda K; Orime K; Kubota N; Kadowaki T; Terauchi Y
Endocrinology; 2012 Mar; 153(3):1093-102. PubMed ID: 22315446
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats.
Sain H; Sharma B; Jaggi AS; Singh N
Neuroscience; 2011 Sep; 192():322-33. PubMed ID: 21777659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
